药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(20195623191010.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文Stendra处方资料(仅供参考)
【英文名称】Stendra
【适用证】
STENDRA是一种磷酸二酯酶5(PDE5)抑制剂,用于治疗勃起功能障碍(1)
【用法用量】
- 起始剂量为100 mg,最早在性活动前约15分钟,根据需要(2.1)
- 每天不超过一次服用STENDRA(2.1)。
- 基于功效和/或耐受性,剂量可以在性活动前约15分钟增加至200mg,或在性活动前约30分钟减少至50mg。 使用提供益处的最低剂量(2.1)。
- STENDRA可带或不带食物(2.2)
- 不要将STENDRA与强CYP3A4抑制剂一起使用(2.3)
- 如果服用中度CYP3A4抑制剂,剂量应在24小时内不超过50毫克(2.3)。
- 对于稳定α受体阻滞剂治疗的患者,推荐的STENDRA起始剂量为50 mg(2.3)。
【禁忌】
---禁止向使用任何形式有机硝酸盐的患者施用STENDRA(4.1)
---对STENDRA平板电脑任何组件过敏(4.2)
---用鸟苷酸环化酶(GC)刺激剂如riociguat(4.3)给药
【使用注意】
- 如果由于心血管状况或任何其他原因导致性活动不可取,患者不应使用STENDRA(5.1)
- 使用STENDRA与α-受体阻滞剂,其他抗高血压药物或大量酒精(大于3个单位)可能导致低血压(2.3,5.6,5.7)
- 如果勃起持续时间超过4小时,患者应寻求紧急治疗(5.3)
- 如果一只或两只眼睛突然失明,患者应该停止STENDRA并寻求医疗护理,这可能是非动脉缺血性视神经病变(NAION)的征兆。 STENDRA应谨慎使用,并且只有在具有NAION病史的患者中,预期益处大于风险时才应使用。 患有“拥挤”视盘的患者也可能患NAION的风险增加(5.4,6.2)
- 如果突然减少或失去听力,患者应停止服用STENDRA并立即就医(5.5)
【INDICATIONS AND USAGE】
STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (1)
【DOSAGE AND ADMINISTRATION】
--The starting dose is 100 mg taken as early as approximately 15 minutes before sexual activity, on an as needed basis (2.1)
--Take STENDRA no more than once a day (2.1).
--Based on efficacy and/or tolerability, the dose may be increased to 200 mg taken as early as approximately 15 minutes before sexual activity, or decreased to 50 mg taken approximately 30 minutes before sexual activity. Use the lowest dose that provides benefit (2.1).
--STENDRA may be taken with or without food (2.2)
--Do not use STENDRA with strong CYP3A4 inhibitors (2.3)
--If taking a moderate CYP3A4 inhibitor, the dose should be no more than 50 mg in a 24-hour period (2.3).
--In patients on stable alpha-blocker therapy, the recommended starting dose of STENDRA is 50 mg (2.3).
【CONTRAINDICATIONS】
---Administration of STENDRA to patients using any form of organic nitrate is contraindicated (4.1)
---Hypersensitivity to any component of the STENDRA tablet (4.2)
---Administration with guanylate cyclase (GC) stimulators such as riociguat (4.3)
【WARNINGS AND PRECAUTIONS】
--Patients should not use STENDRA if sexual activity is inadvisable due to cardiovascular status or any other reason (5.1)
--Use of STENDRA with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension (2.3, 5.6, 5.7)
--Patients should seek emergency treatment if an erection lasts greater than 4 hours (5.3)
--Patients should stop STENDRA and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of Non Arteritic Ischemic Optic Neuropathy (NAION). STENDRA should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a “crowded” optic disc may also be at an increased risk of NAION (5.4, 6.2)
--Patients should stop taking STENDRA and seek prompt medical attention in the event of sudden decrease or loss of hearing (5.5)
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(20195623191010.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- |